Abstract
In the wake of disappointing results from the first phase 3 immune intervention trials in type 1 diabetes mellitus, a report by Tihamer Orban and colleagues in The Lancet1 could provide a much desired glimmer of hope that the course of disease progression can be altered by immunotherapy after all. Treatment of patients with recent-onset type 1 diabetes for 2 years with abatacept (CTLA4 immunoglobulin fusion protein), believed to interfere with priming and activation of T cells, effectively delayed loss of β-cell function for 9 months.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
